scholarly journals Second primary malignancies in adult acute lymphoblastic leukemia: a US population–based study

Blood ◽  
2014 ◽  
Vol 124 (12) ◽  
pp. 2000-2001 ◽  
Author(s):  
Krishna Bilas Ghimire ◽  
Binay Kumar Shah
eJHaem ◽  
2021 ◽  
Author(s):  
Emma Bergfelt Lennmyr ◽  
Marie Engvall ◽  
Gisela Barbany ◽  
Linda Fogelstrand ◽  
Hanna Rhodin ◽  
...  

PLoS ONE ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. e0152909
Author(s):  
Chung-Jen Teng ◽  
Leh-Kiong Huon ◽  
Yu-Wen Hu ◽  
Chiu-Mei Yeh ◽  
Sheng-Hsuan Chien ◽  
...  

2021 ◽  
Vol 11 (11) ◽  
Author(s):  
Manette A. W. Dinnessen ◽  
Otto Visser ◽  
Sanne H. Tonino ◽  
Eduardus F. M. Posthuma ◽  
Nicole M. A. Blijlevens ◽  
...  

2018 ◽  
Vol 2 (8) ◽  
pp. 895-903 ◽  
Author(s):  
Lori Muffly ◽  
Elysia Alvarez ◽  
Daphne Lichtensztajn ◽  
Renata Abrahão ◽  
Scarlett Lin Gomez ◽  
...  

Key Points Two-thirds of AYA ALL are treated in the adult cancer setting; one-quarter of AYAs in this setting receive front-line pediatric ALL therapy. Survival was superior for AYA ALL patients treated in pediatric cancer settings and in NCI-designated cancer centers.


2020 ◽  
Vol 29 (6) ◽  
pp. 538-545
Author(s):  
Jeremiah Hwee ◽  
Rinku Sutradhar ◽  
Jeffrey C. Kwong ◽  
Lillian Sung ◽  
Stephanie Cheng ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2759
Author(s):  
Shlomit Barzilai-Birenboim ◽  
Ronit Nirel ◽  
Nira Arad-Cohen ◽  
Galia Avrahami ◽  
Miri Ben Harush ◽  
...  

Venous thromboembolism (VTE) is a serious complication of acute lymphoblastic leukemia (ALL) therapy. The aim of this population-based study was to evaluate the rate, risk factors, and long-term sequelae of VTE in children treated for ALL. The cohort included 1191 children aged 1–19 years diagnosed with ALL between 2003–2018, prospectively enrolled in two consecutive protocols: ALL-IC BFM 2002 and AIEOP-BFM ALL 2009. VTEs occurred in 89 patients (7.5%). Long-term sequelae were uncommon. By univariate analysis, we identified four significant risk factors for VTEs: Severe hypertriglyceridemia (p = 0.005), inherited thrombophilia (p < 0.001), age >10 years (p = 0.015), and high-risk ALL group (p = 0.039). In addition, the incidence of VTE was significantly higher in patients enrolled in AIEOP-BFM ALL 2009 than in those enrolled in ALL-IC BFM 2002 (p = 0.001). Severe VTE occurred in 24 children (2%), all of whom had at least one risk factor. Elevated triglyceride levels at diagnosis did not predict hypertriglyceridemia during therapy. In a multivariate analysis of 388 children, severe hypertriglyceridemia and inherited thrombophilia were independent risk factors for VTE. Routine evaluation for these risk factors in children treated for ALL may help identify candidates for intervention.


2013 ◽  
Vol 169 (5) ◽  
pp. 577-585 ◽  
Author(s):  
Chang-Hsien Lu ◽  
Kuan-Der Lee ◽  
Ping-Tsung Chen ◽  
Chih-Cheng Chen ◽  
Feng-Che Kuan ◽  
...  

ObjectiveMost studies on second primary malignancies (SPMs) after primary thyroid cancer were conducted in USA or Europe. The discrepancy between SPMs in these studies could be attributed to geographical and ethnic heterogeneity. Thus, there is a clear need for another large-scale epidemiological study, particularly in Asian countries, to define the incidence and risk of SPMs in thyroid cancer survivors.DesignA population-based study was conducted using the nation-wide database from Taiwan Cancer Registry between 1979 and 2006.MethodsWe quantified standardized incidence ratios (SIRs) and cumulative incidence of SPMs among 19 068 individuals (4205 males and 14 863 females) with primary thyroid cancer.ResultsA total of 644 cases (3.38%) developed at least a SPM during 134 678 person-years of follow-up. The risk for subsequent SPMs was significantly greater than that of the general population (SIR=1.33, 95% CI 1.23–1.44). There was a greater risk of developing major salivary glands, nasopharyngeal, lung, thymus, breast (females), bladder, and brain cancers, and leukemia and lymphoma. We observed that the risk was highest within the first 5 years of diagnosis of thyroid cancer (SIR=5.29, 1.68, and 0.68 for ≦5, 5–10, and >10 respectively) and in the younger patients (SIR=1.81 vs 1.61 for <50 and ≧50 respectively). The median overall survival for primary thyroid cancer patients was 23.28 years, but it was only 4.73 years for those who developed SPMs.ConclusionThyroid cancer is associated with a 33% risk increment of SPMs, which had a negative impact on survival. There are sites of SPMs in the Asian population that are distinctive from those in the Western population, suggesting that other genetic predisposition or environmental factors may play a role.


Sign in / Sign up

Export Citation Format

Share Document